Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis.
Hilger
R A
RA
Department of Internal Medicine, University of Essen Medical School, Essen, Germany. ralf.hilger@uni-duisburg-essen.de
Richly
H
H
Grubert
M
M
Kredtke
S
S
Thyssen
D
D
Eberhardt
W
W
Hense
J
J
Schuler
M
M
Scheulen
M E
ME
D000970:Antineoplastic Agents / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001800:Blood Specimen Collection; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011725:Pyridines / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006435:Renal Dialysis; D000077157:Sorafenib; D013997:Time Factors
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; C013229:pyridine N-oxide; D000077157:Sorafenib